早期改用芬戈莫德可能会降低那他珠单抗中断治疗后疾病复发的风险。 - Suppr

Suppr

超能文献

Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption.

作者信息

Laroni A, Brogi D, Milesi V, Abate L, Uccelli A, Mancardi Gl

出版信息

Mult Scler. 2013 Aug;19(9):1236-7. doi: 10.1177/1352458512468498. Epub 2012 Nov 26.

DOI:10.1177/1352458512468498

PMID:23184503

Abstract

摘要

相似文献

Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption.

Mult Scler. 2013 Aug;19(9):1236-7. doi: 10.1177/1352458512468498. Epub 2012 Nov 26.

Natalizumab to fingolimod: Questions answered, unanswered, and unasked.

Neurology. 2015 Jul 7;85(1):14-5. doi: 10.1212/WNL.0000000000001722. Epub 2015 May 29.

Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings.

Mult Scler. 2012 Nov;18(11):1640-3. doi: 10.1177/1352458512464282.

Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal.

Mult Scler. 2012 Nov;18(11):1647-9. doi: 10.1177/1352458512458009. Epub 2012 Aug 20.

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.

Ann Neurol. 2015 Mar;77(3):425-35. doi: 10.1002/ana.24339. Epub 2015 Jan 17.

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.

Neurology. 2015 Jul 7;85(1):29-39. doi: 10.1212/WNL.0000000000001706. Epub 2015 May 29.

Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod.

Mult Scler. 2012 Nov;18(11):1650-2. doi: 10.1177/1352458512463768.

Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases.

Mult Scler. 2012 Nov;18(11):1636-9. doi: 10.1177/1352458512454773. Epub 2012 Jul 24.

Comment on 'Fingolimod to treat severe MS after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?' Maillart et al.

Mult Scler. 2014 Apr;20(4):510-1. doi: 10.1177/1352458513517281. Epub 2014 Jan 27.

Switching from natalizumab to fingolimod: an observational study.

Acta Neurol Scand. 2013 Aug;128(2):e6-e10. doi: 10.1111/ane.12082. Epub 2013 Jan 22.

引用本文的文献

Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod.

Ther Adv Neurol Disord. 2018 Aug 9;11:1756286418791103. doi: 10.1177/1756286418791103. eCollection 2018.

Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.

J Neurol. 2016 Aug;263(8):1511-7. doi: 10.1007/s00415-016-8162-8. Epub 2016 May 18.

Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations.

Ther Clin Risk Manag. 2016 Feb 19;12:261-72. doi: 10.2147/TCRM.S65558. eCollection 2016.

Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis.

Drug Healthc Patient Saf. 2015 Dec 11;7:157-67. doi: 10.2147/DHPS.S69640. eCollection 2015.

Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers.

Neurol Ther. 2015 Dec;4(2):147-57. doi: 10.1007/s40120-015-0038-9. Epub 2015 Dec 8.

Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report.

BMC Neurol. 2015 Dec 7;15:252. doi: 10.1186/s12883-015-0512-0.

Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor).

BMC Neurol. 2015 Jun 23;15:96. doi: 10.1186/s12883-015-0354-9.

An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations.

Patient Prefer Adherence. 2015 May 19;9:675-84. doi: 10.2147/PPA.S20791. eCollection 2015.

Recurrence of disease activity after repeated Natalizumab withdrawals.

Neurol Sci. 2015 Mar;36(3):465-7. doi: 10.1007/s10072-014-1960-9. Epub 2014 Sep 24.

Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients.

J Neurol. 2014 Jun;261(6):1170-7. doi: 10.1007/s00415-014-7325-8. Epub 2014 Apr 12.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验